"Providing access to our medicines is very important, so we are pleased to have resolved this pre-acquisition matter, and that all Bausch + Lomb products will continue to be available to patients, including those covered under government reimbursement programs," said Dan Wechsler, executive vice president and president, Global Pharmaceuticals, Bausch + Lomb.About Bausch + Lomb Bausch + Lomb is a leading global eye health company that is solely focused on protecting, enhancing, and restoring people's eyesight. Our core businesses include ophthalmic pharmaceuticals, contact lenses and lens care products, and ophthalmic surgical devices and instruments. We globally develop, manufacture and market one of the most comprehensive product portfolios in our industry, which are available in more than 100 countries. Founded in 1853, our company is headquartered in Rochester, NY, and employs more than 11,000 people worldwide.
Bausch + Lomb Announces Settlement With The U.S. Department Of Justice To Resolve And Conclude ISTA Pharmaceuticals Investigation
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts